Education
About Us
Working with TipRanks
Follow Us
Revive Therapeutics Ltd (TSE:RVV)
:RVV
RVV Stock Chart & Stats
C$0.01
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.01
C$0.00(0.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.04
Previous CloseN/A
Volume2.50K
Average Volume (3M)285.50K
Market Cap
C$4.19M
Enterprise ValueC$6.52M
Total Cash (Recent Filing)C$30.95K
Total Debt (Recent Filing)C$68.18K
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding418,564,270
10 Day Avg. Volume295,136
30 Day Avg. Volume285,498
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)0.00
P/FCF Ratio-10.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Absolute Debt BurdenVery low absolute debt reduces fixed financing costs and near-term solvency pressure, providing structural flexibility. Over the next 2–6 months this limits interest drain and gives management more optionality when raising capital or prioritizing programs.
Reduced Cash Burn Versus Prior YearsMaterial reduction in cash outflows versus the multi‑million annual burn of earlier years indicates management has materially slowed spending. This structural decline in burn improves runway and lowers immediate financing frequency risk over the medium term.
Clinical-stage Pipeline In Psychedelics & RepurposingOwning proprietary and in‑licensed candidates in the growing psychedelic medicines and drug‑repurposing spaces offers structural upside: clinical progress or partnerships can de‑risk programs and create lasting value beyond short‑term market moves.
Bears Say
No Revenue; Persistent Large LossesLack of revenue and substantial trailing losses mean the business remains pre‑commercial and dependent on external funding. Over 2–6 months this structural revenue absence constrains cash flow generation and heightens execution and financing risk for development programs.
Negative Shareholders' Equity And Asset ErosionThe sharp deterioration to negative equity and a collapsed asset base reduces financial flexibility and borrowing capacity. Structurally this raises the probability of dilution or distressed financing and limits collateral for partnerships or non‑dilutive capital in the medium term.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow means the company cannot self‑fund development and will need recurring external capital. This persistent cash burn structurally pressures program continuity and prioritization decisions across the next several quarters.
Revive Therapeutics News
RVV FAQ
What was Revive Therapeutics Ltd’s price range in the past 12 months?
Revive Therapeutics Ltd lowest stock price was <C$0.01 and its highest was C$0.04 in the past 12 months.
What is Revive Therapeutics Ltd’s market cap?
Revive Therapeutics Ltd’s market cap is C$4.19M.
When is Revive Therapeutics Ltd’s upcoming earnings report date?
Revive Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2026 which is in 9 days.
How were Revive Therapeutics Ltd’s earnings last quarter?
Currently, no data Available
Is Revive Therapeutics Ltd overvalued?
According to Wall Street analysts Revive Therapeutics Ltd’s price is currently Overvalued.
Does Revive Therapeutics Ltd pay dividends?
Revive Therapeutics Ltd does not currently pay dividends.
What is Revive Therapeutics Ltd’s EPS estimate?
Revive Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Revive Therapeutics Ltd have?
Revive Therapeutics Ltd has 418,564,270 shares outstanding.
What happened to Revive Therapeutics Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Revive Therapeutics Ltd?
Currently, no hedge funds are holding shares in TSE:RVV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---